News

June 21, 2017

Regulus Therapeutics Announces Changes to Phase 2 Trial for RG-012 in Alport Syndrome

News

Regulus Therapeutics, a pharmaceutical company dedicated to the development of microRNA treatments, announced that the design of the Phase 2 clinical program to test its product RG-012 as a potential ... Read more

June 12, 2017

Regulus Back on Track with RG-012 Clinical Development for Alport Syndrome

Alport syndrome news, News

Regulus Therapeutics has completed dosing of its Alport syndrome drug candidate RG-012 in a Phase 1 trial testing several ascending doses of the treatment in healthy volunteers. The treatment ... Read more

June 9, 2017June 9, 2017

Alport Syndrome Foundation’s Virtual Walk Kicks Off June 17

Alport syndrome news, News

The Alport Syndrome Foundation (ASF) welcomes all who are interested to take part in its 2nd Annual Virtual Walk, a fundraising event to help fight Alport syndrome. Virtual walk participants can walk anytime, anywhere, ... Read more

June 7, 2017

New Gene Screening Method, Whole-Exome Sequencing, Seen to Help in Diagnosing Alport Syndrome

News

Genetic screening helps in diagnosing Alport syndrome, a difficult-to-diagnose disease, although its rate of success is still far from ideal and mutations in at least one-fifth of all patients are ... Read more

June 1, 2017

Researchers Identify New Gene Mutations Related to Alport Syndrome

News

Fifteen new mutations and two new deletions have been identified in three genes that encode for type 4 collagen in Alport syndrome patients. These new findings are now added ... Read more

May 12, 2017May 12, 2017

Reata Tests Bardoxolone Methyl as Possible Treatment for Loss of Kidney Activity in Alport Syndrome

News

Reata Pharmaceuticals is investigating bardoxolone methyl as a potential treatment for chronic kidney disease (CKD) triggered by Alport syndrome. The CARDINAL (NCT03019185) Phase 2/3 clinical trial — which is ... Read more

April 25, 2017

Single-point Mutation in Critical Gene Seen to Cause Key Alport Symptoms

News

A single-point mutation in a critical gene, AMMECR1, is responsible for the physical expression of the main symptoms associated with Alport syndrome, researchers report. This finding is detailed in the study ... Read more

April 21, 2017April 21, 2017

Alport Syndrome Foundation Among 14 Groups Awarded Global Genes’ RARE Patient Grants

News

The Alport Syndrome Foundation is one of 14 patient advocacy organizations that has received Global Genes‘ 2017 RARE Patient Impact Grants, for their work supporting patient communities of rare diseases. The initiative was ... Read more

April 7, 2017April 7, 2017

Regulus Drug Candidate RG-012 to Treat Kidney Damage in Alport Patients Begins Phase 1 Clinical Trials

News

RG-012, a drug to treat renal function decline in patients with Alport syndrome, is moving into Phase 1 clinical trial, says its developer, Regulus Therapeutics. The company, based in La ... Read more

April 3, 2017April 3, 2017

Report Describes Teenager with 2 Rare Diseases: Alport Syndrome and ANCA-Associated Vasculitis

News

Doctors recently reported the case of a 17-year-old boy with Alport syndrome who developed an even more rare disease — ANCA-associated vasculitis — and was successfully treated. This is the first-ever ... Read more